# Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss | This GLP A mediation analysis of a phase 2 MASH trial found 77.4% of survodutide's liver fat effect ran through weight loss, against 36.3% for fibrosis improvement. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/liver-repair-that-was-not-the-weight Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss A mediation analysis of a phase 2 survodutide trial split its liver effects in two. Roughly three quarters of the fat reduction tracked weight loss; only a third of the fibrosis improvement did. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 How much of the effect ran through weight loss · liver fat (FibroScan CAP) · 77.4% · MASH improvement · 71.8% · MASH resolution · 66.7% · liver fat (MRI) · 58.2% · fibrosis improvement · 36.3% · AST · 16.5% · Remainder is attributed to a direct drug effect. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A post hoc mediation analysis of a phase 2 MASH trial split survodutide's liver effects into a part running through weight loss and a part not. - Fat responded to weight: 77.4% and 58.2% of the effect on the two steatosis measures was weight-mediated. - Scarring largely did not: only 36.3% of the effect on fibrosis improvement, and 16.5% to 38.6% for the inflammation and fibrosis blood markers. - Mediation analysis apportions an effect using assumptions that cannot be checked against the data. Survodutide is investigational and not on sale. If a drug improves a fatty liver, the interesting question is whether it did anything the weight loss would not have done by itself. A post hoc analysis of a phase 2 trial in MASH tried to answer it directly, taking participants (n = 170) with stage F2 to F3 fibrosis and paired biopsies and apportioning each liver outcome between a weight-dependent and a weight-independent path [\[1\]](https://thisglp.com/research/liver-repair-that-was-not-the-weight#ref-1). The comparison between the marketed drugs on liver endpoints is in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). The pattern that emerged is cleaner than these analyses usually produce. Liver fat behaved like a weight problem: 77.4% of the effect on the FibroScan attenuation measure and 58.2% of the effect on MRI-measured fat fraction ran through weight reduction. So did most of the effect on MASH itself, at 66.7% for resolution and 71.8% for improvement. Fibrosis behaved differently. Only 36.3% of the effect on fibrosis improvement was attributed to weight, leaving the majority to a direct action of the drug. The blood markers pointed the same way, with weight mediating between 16.5% for AST and 38.6% for the Enhanced Liver Fibrosis score. The authors suggest glucagon receptor agonism as the route, which is what distinguishes survodutide from a pure GLP-1 drug, and places it among the multi-receptor agents surveyed in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). A mediation percentage is a model output This kind of analysis divides an observed effect between two paths by assuming, among other things, that nothing unmeasured causes both the weight change and the liver change. That assumption cannot be tested against the data it is applied to. "66.7% mediated by weight reduction" is therefore a statement about a model, not a measurement anyone made, and a different set of covariates would produce a different split. Three further limits keep this in proportion. It is post hoc, so the questions were chosen after the results were known. It pools the dose arms, discarding the dose-response information that is the main output of a phase 2 trial. And 170 participants with biopsies at both ends is a small number on which to divide six separate effects in two. Survodutide is investigational and cannot be bought, so nothing here is a recommendation about anything currently available. What it contributes is a mechanistic claim worth testing properly: that in the liver, the fat and the scarring may respond to different things, and a drug that only removes weight may do less for the second. That would matter for the marketed drugs too, whose liver results are usually reported without this separation — as are their effects on body composition generally, covered in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and in [the pooled weight figures](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## Frequently asked Does this mean the drug helps the liver beyond weight loss? It suggests so for scarring specifically, where only 36.3% of the effect was attributed to weight. But a mediation analysis apportions effects using assumptions that cannot be verified, so this is a hypothesis with numbers attached. Can I get survodutide? No. It is investigational and not approved or on sale anywhere as of this writing. Why did liver fat and fibrosis behave differently? The authors propose direct glucagon receptor agonism, which survodutide has and pure GLP-1 drugs do not. That would act on the liver independently of how much weight someone loses. ## Sources 1. \[1\] Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2026). Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Hepatology. [PMID 42545725](https://pubmed.ncbi.nlm.nih.gov/42545725/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)